Psychotic Disorders - New Zealand

Revenue in the Psychotic Disorders market is projected to reach US$3.52m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.14%, resulting in a market volume of US$3.54m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$31.65 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in New Zealand is experiencing significant growth and development.

Customer preferences: Customers in New Zealand are increasingly seeking effective treatments and therapies for psychotic disorders. They are looking for medications that can effectively manage symptoms and improve their quality of life. Additionally, there is a growing preference for non-pharmacological interventions, such as psychotherapy and cognitive-behavioral therapy, which can help individuals develop coping strategies and manage their symptoms.

Trends in the market: One of the key trends in the Psychotic Disorders market in New Zealand is the increasing adoption of innovative treatment options. Pharmaceutical companies are investing in research and development to introduce new medications that are more targeted and have fewer side effects. This trend is driven by the demand for more personalized and effective treatments.Another trend in the market is the integration of technology in the management of psychotic disorders. Mobile applications and online platforms are being developed to provide support and resources for individuals with psychotic disorders. These digital solutions offer tools for self-monitoring, medication reminders, and access to online support communities. This trend is driven by the increasing use of smartphones and the desire for convenient and accessible healthcare solutions.

Local special circumstances: New Zealand has a well-established healthcare system that provides access to mental health services for individuals with psychotic disorders. The government has implemented initiatives to reduce stigma and improve access to treatment and support services. This includes the provision of community-based mental health teams and the development of early intervention programs. These efforts contribute to the growth of the Psychotic Disorders market in New Zealand by increasing awareness and improving access to care.

Underlying macroeconomic factors: The growing prevalence of psychotic disorders in New Zealand is a key macroeconomic factor driving the development of the market. Factors such as aging population, urbanization, and lifestyle changes contribute to the increasing incidence of psychotic disorders. This creates a larger patient pool and drives the demand for treatments and therapies.Additionally, the government's commitment to mental health and the allocation of resources to improve mental healthcare services also play a role in the growth of the market. The government's investment in mental health infrastructure and services creates opportunities for pharmaceutical companies and healthcare providers to expand their offerings and meet the growing demand.In conclusion, the Psychotic Disorders market in New Zealand is experiencing growth and development due to customer preferences for effective treatments, the adoption of innovative options, the integration of technology, local special circumstances such as a well-established healthcare system, and underlying macroeconomic factors such as the growing prevalence of psychotic disorders and government investment in mental health.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.